Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review ...
Hantavirus is a rare disease, with just 890 cases reported in America between 1993 and 2023. The World Health Organization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results